Biontech Se Stock Analysis

BioNTech Stock Analysis Notes

About 63.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 0.96. Some equities with similar Price to Book (P/B) outperform the market in the long run. BioNTech SE has Price/Earnings To Growth (PEG) ratio of 0.04. The entity last dividend was issued on the 2nd of June 2022. BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany. Biontech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 3082 people. For more info on BioNTech SE please contact Ugur MD at 49 6131 9084 0 or go to https://www.biontech.de.

BioNTech SE Investment Alerts

BioNTech SE Upcoming and Recent Events

BioNTech Largest EPS Surprises

View All Earnings Estimates

BioNTech Thematic Classifications

BioNTech Stock Institutional Investors

Note, although BioNTech's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

BioNTech Market Capitalization

The company currently falls under 'Large-Cap' category with a current market capitalization of 21.9 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate BioNTech's market, we take the total number of its shares issued and multiply it by BioNTech's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

BioNTech Profitablity

The company has Profit Margin (PM) of 0.24 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.4 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.4.

Management Efficiency

BioNTech SE has return on total asset (ROA) of 0.0262 % which means that it generated a profit of $0.0262 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0462 %, meaning that it created $0.0462 on every $100 dollars invested by stockholders. BioNTech's management efficiency ratios could be used to measure how well BioNTech manages its routine affairs as well as how well it operates its assets and liabilities. At this time, BioNTech's Return On Tangible Assets are fairly stable compared to the past year. Return On Assets is likely to rise to 0.07 in 2024, whereas Return On Capital Employed is likely to drop 0.03 in 2024. At this time, BioNTech's Fixed Asset Turnover is fairly stable compared to the past year. Return On Assets is likely to rise to 0.07 in 2024, whereas Debt To Assets are likely to drop 0.01 in 2024.

Technical Drivers

As of the 9th of May, BioNTech shows the Standard Deviation of 1.6, mean deviation of 1.26, and Risk Adjusted Performance of (0.0003). BioNTech SE technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to interpolate and analyze data for thirteen technical drivers for BioNTech SE, which can be compared to its peers. Please confirm BioNTech SE variance and skewness to decide if BioNTech SE is priced correctly, providing market reflects its regular price of 90.13 per share. Given that BioNTech has information ratio of (0.07), we suggest you to validate BioNTech SE's prevailing market performance to make sure the company can sustain itself at a future point.

BioNTech SE Price Movement Analysis

BioNTech Predictive Daily Indicators

BioNTech Corporate Filings

BioNTech Forecast Models

BioNTech's time-series forecasting models are one of many BioNTech's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary BioNTech's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how BioNTech prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling BioNTech shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as BioNTech. By using and applying BioNTech Stock analysis, traders can create a robust methodology for identifying BioNTech entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. BioNTech analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. BioNTech analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

BioNTech SE stock analysis indicators help investors evaluate how BioNTech stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading BioNTech shares will generate the highest return on investment. By understating and applying BioNTech stock analysis, traders can identify BioNTech position entry and exit signals to maximize returns.

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioNTech SE. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.

When running BioNTech's price analysis, check to measure BioNTech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioNTech is operating at the current time. Most of BioNTech's value examination focuses on studying past and present price action to predict the probability of BioNTech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioNTech's price. Additionally, you may evaluate how the addition of BioNTech to your portfolios can decrease your overall portfolio volatility.

Is BioNTech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioNTech. If investors know BioNTech will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioNTech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

The market value of BioNTech SE is measured differently than its book value, which is the value of BioNTech that is recorded on the company's balance sheet. Investors also form their own opinion of BioNTech's value that differs from its market value or its book value, called intrinsic value, which is BioNTech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioNTech's market value can be influenced by many factors that don't directly affect BioNTech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between BioNTech's value and its price as these two are different measures arrived at by different means. Investors typically determine if BioNTech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioNTech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.